Equities Analysts Set Expectations for Zevra Therapeutics, Inc.'s FY2025 Earnings (NASDAQ:ZVRA)

Zevra Therapeutics, Inc. (NASDAQ:ZVRA - Free Report) - Equities research analysts at HC Wainwright reduced their FY2025 earnings per share (EPS) estimates for Zevra Therapeutics in a research note issued to investors on Wednesday, April 3rd. HC Wainwright analyst O. Livnat now anticipates that the company will earn $0.49 per share for the year, down from their previous forecast of $0.63. HC Wainwright currently has a "Buy" rating and a $15.00 target price on the stock. The consensus estimate for Zevra Therapeutics' current full-year earnings is ($1.49) per share. HC Wainwright also issued estimates for Zevra Therapeutics' FY2028 earnings at $3.01 EPS.

A number of other equities analysts have also recently issued reports on the company. Cantor Fitzgerald restated an "overweight" rating on shares of Zevra Therapeutics in a report on Monday. William Blair reiterated an "outperform" rating on shares of Zevra Therapeutics in a report on Tuesday, March 12th. Finally, Maxim Group increased their target price on Zevra Therapeutics from $12.00 to $18.00 and gave the stock a "buy" rating in a report on Tuesday. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock has a consensus rating of "Buy" and an average price target of $19.50.

Zevra Therapeutics Trading Down 2.4 %

Shares of Zevra Therapeutics stock traded down $0.12 on Thursday, reaching $4.91. 263,380 shares of the company's stock were exchanged, compared to its average volume of 260,434. The company has a market capitalization of $177.84 million, a P/E ratio of -3.81 and a beta of 1.81. Zevra Therapeutics has a 52 week low of $3.89 and a 52 week high of $7.28. The firm's 50-day moving average is $6.11 and its two-hundred day moving average is $5.37. The company has a debt-to-equity ratio of 0.65, a quick ratio of 6.31 and a current ratio of 6.31.

Institutional Investors Weigh In On Zevra Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of ZVRA. Public Employees Retirement System of Ohio increased its position in shares of Zevra Therapeutics by 52.5% during the 4th quarter. Public Employees Retirement System of Ohio now owns 5,337 shares of the company's stock valued at $35,000 after purchasing an additional 1,837 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Zevra Therapeutics by 17.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 35,703 shares of the company's stock valued at $234,000 after purchasing an additional 5,337 shares during the last quarter. Tower Research Capital LLC TRC increased its holdings in Zevra Therapeutics by 134.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 9,673 shares of the company's stock worth $63,000 after acquiring an additional 5,545 shares during the last quarter. International Assets Investment Management LLC increased its holdings in Zevra Therapeutics by 555.0% in the 4th quarter. International Assets Investment Management LLC now owns 6,550 shares of the company's stock worth $43,000 after acquiring an additional 5,550 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in Zevra Therapeutics by 6.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 96,130 shares of the company's stock worth $630,000 after acquiring an additional 5,698 shares during the last quarter. 35.03% of the stock is owned by hedge funds and other institutional investors.

Zevra Therapeutics Company Profile

Zevra Therapeutics, Inc, a rare disease company melding science, discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company utilizes its Ligand Activated Therapy technology to generate improved prodrug versions of FDA-approved drugs, as well as to generate prodrug versions of existing compounds that may have applications for new disease indications.